Aktive Positionen von Bernard Pau
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
Phost’in SAS
 Phost’in SAS Pharmaceuticals: MajorHealth Technology Phost’In SAS operates as a biotechnology company, which engages in the discovery and development of N-glycosylation inhibitors. Its potent anti-cancer new chemical entities specifically targeting abnormal pathogenic glycosylation mechanisms. The company was founded by Karine Chorro and Ludovic Clarion in December 2014 and is headquartered in France. | Vorsitzender | 17.06.2020 | - |
| Geschäftsführer | 17.06.2020 | - |
Karriereverlauf von Bernard Pau
Ehemalige bekannte Positionen von Bernard Pau
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
Biodol Therapeutics SAS
 Biodol Therapeutics SAS BiotechnologyHealth Technology Biodol Therapeutics SAS engages in the development of compounds for the treatment of chronic pain. It specializes in parallel small-molecule FLT3 inhibitors. The company was founded by Fabien Granier, Pierre Sokoloff and Bernard Pau in 2015 and is headquartered in Clapiers, France. | Gründer | 01.01.2015 | - |
Statistik
International
| Frankreich | 3 |
Operativ
| Chairman | 1 |
| Chief Operating Officer | 1 |
| Founder | 1 |
Sektoral
| Health Technology | 3 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Private Unternehmen | 2 |
|---|---|
Phost’in SAS
Phost’in SAS Pharmaceuticals: MajorHealth Technology Phost’In SAS operates as a biotechnology company, which engages in the discovery and development of N-glycosylation inhibitors. Its potent anti-cancer new chemical entities specifically targeting abnormal pathogenic glycosylation mechanisms. The company was founded by Karine Chorro and Ludovic Clarion in December 2014 and is headquartered in France. | Health Technology |
Biodol Therapeutics SAS
Biodol Therapeutics SAS BiotechnologyHealth Technology Biodol Therapeutics SAS engages in the development of compounds for the treatment of chronic pain. It specializes in parallel small-molecule FLT3 inhibitors. The company was founded by Fabien Granier, Pierre Sokoloff and Bernard Pau in 2015 and is headquartered in Clapiers, France. | Health Technology |
- Börse
- Insiders
- Bernard Pau
- Erfahrung
